Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

by | Mar 3, 2026 | General

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Perrigo Company PLC (NYSE:PRGO)

  • Dividend Yield: 9.40%
  • Canaccord Genuity analyst Susan Anderson maintained a Buy rating and cut the price target from $20 to $17 on Feb. 27, 2026. This analyst has an accuracy rate of 62%.
  • JP Morgan analyst Chris Scott maintained a Neutral rating and slashed the price target from $20 to $18 on Dec. 15, 2025. This analyst has an accuracy rate of 67%
  • Recent News: On Feb. 26, Perrigo posted mixed quarterly results.
  • Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.

Pfizer Inc (NYSE:PFE)

  • Dividend Yield: 6.31%
  • Argus Research analyst David Toung upgraded the stock from Hold to Buy with a price target of $35 on March 2, 2026. This analyst has an accuracy rate of 67%.
  • RBC Capital analyst Trung Huynh initiated coverage on the stock with an Underperform rating and a price target of $25 on Feb. 25, 2026. This analyst has an accuracy rate of 75%
  • Recent News: On Feb. 27, Pfizer and Astellas Pharma announced results from Phase 3 EV-304 clinical trial for PADCEVTM in combination with Keytruda in patients with MIBC eligible for cisplatin-based chemotherapy.
  • Benzinga Pro’s real-time newsfeed alerted to latest PFE news

DENTSPLY SIRONA Inc (NASDAQ:XRAY)

  • Dividend Yield: 4.47%
  • Mizuho analyst Steven Valiquette maintained a Neutral rating and raised the price target from $14 to $16 on March 2, 2026 This analyst has an accuracy rate of 58%.
  • Barrington Research analyst Michael Petusky maintained an Outperform and increased the price target from $14 to $17 on March 2, 2026. This analyst has an accuracy rate of 53%.
  • Recent News: On Feb. 26, Dentsply Sirona reported better-than-expected fourth-quarter sales results.
  • Benzinga Pro’s real-time newsfeed alerted to latest XRAY news

Photo via Shutterstock